 |
|
National Trends in Antiarrhythmic and Antithrombotic Medication Use in Atrial Fibrillation
Margaret C. Fang, MD, MPH;
Randall S. Stafford, MD, PhD;
Jeremy N. Ruskin, MD;
Daniel E. Singer, MD
Arch Intern Med. 2004;164:55-60.
Background Atrial fibrillation is the most common cardiac arrhythmia associated with significant medical complications. We examined trends in the medical therapy of atrial fibrillation in the United States from 1991 through 2000.
Methods Data from 1355 visits among patients with atrial fibrillation were obtained from the National Ambulatory Medical Care Survey, a nationally representative assessment of office-based practice. We assessed trends in medication use for ventricular rate control (digoxin,  -blockers, and calcium channel blockers), sinus rhythm maintenance (class IA, IC, and III antiarrhythmics), and thromboembolism prevention (oral anticoagulants and aspirin).
Results Overall rate control medication use decreased from 72% of visits in 1991-1992 to 56% in 1999-2000 (P = .01 for trend) due to declining digoxin use (64% to 37%, P<.001 for trend). -Blocker and calcium channel blocker use remained unchanged. Although there was no change in overall sinus rhythm medication use over time, amiodarone hydrochloride use increased from 0.2% to 6.4% (P<.001 for trend), while quinidine use decreased from 5.0% to 0.0% (P = .01 for trend). Oral anticoagulant use increased (28% to 41%, P = .01 for trend), with the greatest increase in patients aged 80 years and older (14% to 48%, P<.001 for trend). Despite this, only 46.5% of patients at high risk for stroke were taking anticoagulants in 1999-2000.
Conclusions Digoxin use in atrial fibrillation decreased over time, without concomitant increases in -blocker or calcium channel blocker use. Amiodarone replaced quinidine as the dominant sinus rhythm medication. Although oral anticoagulant use increased over time, particularly in the oldest patients, fewer than half of the patients at high risk for stroke were anticoagulated.
From the Massachusetts General Hospital, Boston (Drs Fang, Ruskin, and Singer); and Stanford Center for Research in Disease Prevention, Stanford University, Palo Alto, Calif (Dr Stafford). Dr Fang is now with the Department of Medicine, University of California, San Francisco. The authors have no relevant financial interest in this article.
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Delivery of Optimized Anticoagulant Therapy: Consensus Statement from the Anticoagulation Forum
Garcia et al.
The Annals of Pharmacotherapy 2008;42:979-988.
ABSTRACT
| FULL TEXT
Antithrombotic Therapy in Atrial Fibrillation: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)
Singer et al.
Chest 2008;133:546S-592S.
ABSTRACT
| FULL TEXT
Surgical Treatment of Atrial Fibrillation
Voeller et al.
Card Surg Adult 2008;3:1375-1394.
FULL TEXT
Letter Regarding Article by Hylek et al, "Major Hemorrhage and Tolerability of Warfarin in the First Year of Therapy Among Elderly Patients With Atrial Fibrillation"
Ono et al.
Circulation 2007;116:e538-e538.
FULL TEXT
Quality of Clinical Documentation and Anticoagulation Control in Patients With Chronic Nonvalvular Atrial Fibrillation in Routine Medical Care
Ansell et al.
American Journal of Medical Quality 2007;22:327-333.
ABSTRACT
Trends in Anticoagulation for Atrial Fibrillation in the U.S.: An Analysis of the National Ambulatory Medical Care Survey Database
Rowan et al.
J Am Coll Cardiol 2007;49:1561-1565.
ABSTRACT
| FULL TEXT
The increasing incidence of anticoagulant-associated intracerebral hemorrhage
Flaherty et al.
Neurology 2007;68:116-121.
ABSTRACT
| FULL TEXT
Bleeding risk stratification models in deciding on anticoagulation in patients with atrial fibrillation: a useful complement to stroke risk stratification schema.
Kakar et al.
Chest 2006;130:1296-1299.
FULL TEXT
Long-term mortality after intracerebral hemorrhage
Flaherty et al.
Neurology 2006;66:1182-1186.
ABSTRACT
| FULL TEXT
The Relationship Between Stature and the Prevalence of Atrial Fibrillation in Patients With Left Ventricular Dysfunction
Hanna et al.
J Am Coll Cardiol 2006;47:1683-1688.
ABSTRACT
| FULL TEXT
Impact of adverse events on prescribing warfarin in patients with atrial fibrillation: matched pair analysis
Choudhry et al.
BMJ 2006;332:141-145.
ABSTRACT
| FULL TEXT
Trials and Tribulations of Non-Inferiority: The Ximelagatran Experience
Kaul et al.
J Am Coll Cardiol 2005;46:1986-1995.
ABSTRACT
| FULL TEXT
Time Trends of Ischemic Stroke Incidence and Mortality in Patients Diagnosed With First Atrial Fibrillation in 1980 to 2000: Report of a Community-Based Study
Miyasaka et al.
Stroke 2005;36:2362-2366.
ABSTRACT
| FULL TEXT
Ximelagatran: Oral direct thrombin inhibition as anticoagulant therapy in atrial fibrillation
Halperin
J Am Coll Cardiol 2005;45:1-9.
ABSTRACT
| FULL TEXT
Advanced Age, Anticoagulation Intensity, and Risk for Intracranial Hemorrhage among Patients Taking Warfarin for Atrial Fibrillation
Fang et al.
ANN INTERN MED 2004;141:745-752.
ABSTRACT
| FULL TEXT
|
